Samir Patel
Ophthalmology · Philadelphia, PANPI 1568825057
Payments from drug & device makers
Across 56 payments — averaging $352.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Regeneron$4K
- Bausch & Lomb Americas Inc.$2K
- Genentech USA, Inc.$531
- Endo USA, Inc.$500
- Genentech, Inc.$317
- plus $721 from 6 others
Across 2 payments — averaging $1264.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Consulting fees$16,10582%
- Travel & lodging$1,2476%
- Food & beverage$2,39212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $11,531 |
| Regeneron | 2 | $4,230 |
| Bausch & Lomb Americas Inc. | 9 | $1,915 |
| Genentech USA, Inc. | 9 | $531 |
| Endo USA, Inc. | 1 | $500 |
| Genentech, Inc. | 4 | $317 |
| Apellis Pharmaceuticals, Inc. | 4 | $305 |
| Alcon | 6 | $204 |
| Sight Sciences, Inc. | 1 | $142 |
| Amgen | 2 | $43 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$4,230
- STELLARIS ELITE$1,600
- VABYSMO$359
- Syfovre$251
- OMNI(R) SURGICAL SYSTEM (US)$142
- STELLARIS$138
How this compares
$19,744 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 118 | $5,299 |
| Ketorolac Tromethamine | 69 | $1,287 |
| Atropine Sulfate | 20 | $820 |
| Brimonidine Tartrate | 17 | $697 |
| Dorzolamide Hcl | 29 | $565 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $306 |
| Latanoprost | 20 | $113 |
| Gentamicin Sulfate | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Jonathan MyersPhiladelphia$660K
- Beeran MeghparaPhiladelphia$496K
- Cesar BricenoPhiladelphia$487K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Leslie KatzPhiladelphia$159K
- Durga BorkarPhiladelphia$150K
- Bennie JengPhiladelphia$142K
- Rachel NiknamPhiladelphia$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.